Novo Nordisk's second quarter revenue beats on GLP-1 strength, but impairments hit EPS; company lifts 2026 guidance.

Novo Nordisk reported second quarter 2026 revenue of DKK 78.5 billion ($12.26 billion), beating estimates, while diluted EPS of DKK 4.75 ($0.74) missed expectations due to significant impairment charges. Adjusted operating profit grew 11% at constant exchange rates (CER), driven by strong GLP-1 volume growth. Citing better-than-expected GLP-1 sales, the company raised its full-year 2026 guidance.

Key Highlights

• Q2 2026 adjusted sales increased 7% at CER, led by strong GLP-1 volume growth in both US and International operations.
• Adjusted Obesity Care sales grew 16% at CER in the quarter, with the Wegovy pill showing continued rapid uptake in the US, where total weekly prescriptions exceeded 265,000.
• Reported operating profit fell 16% at CER, heavily impacted by DKK 6.3 billion in non-cash impairment charges related to intangible pipeline assets.
• Novo Nordisk raised its full-year 2026 outlook for adjusted sales growth to 0% to -6% at CER, an improvement from the prior range of -4% to -12%.